Invivyd (NASDAQ:IVVD) Insider Sells $16,896.51 in Stock

Key Points

• Insider Activity: Julie Green, an insider at Invivyd, sold 29,643 shares of stock on August 19th for $16,896.51, reducing her stake in the company by 37.53%.
• Stock Performance: Invivyd's stock price has declined by 1.7% over a recent trading day, reaching $0.5710, with the company facing a significant earnings miss during its last quarterly results.
• Analyst Ratings: The stock has an average rating of "Buy" from analysts, despite some recent price target reductions, with a consensus target of $3.85.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Julie Green sold 29,643 shares of the firm's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total value of $16,896.51. Following the transaction, the insider owned 49,344 shares in the company, valued at approximately $28,126.08. This trade represents a 37.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Julie Green also recently made the following trade(s):

• On Monday, August 18th, Julie Green sold 20,013 shares of Invivyd stock. The shares were sold at an average price of $0.65, for a total transaction of $13,008.45.

Invivyd Stock Down 1.7%

NASDAQ IVVD traded down $0.0101 during trading on Tuesday, reaching $0.5710. 1,690,635 shares of the stock traded hands, compared to its average volume of 850,421. Invivyd, Inc. has a fifty-two week low of $0.3546 and a fifty-two week high of $2.74. The firm has a market cap of $68.60 million, a price-to-earnings ratio of -0.62 and a beta of 0.51. The stock's 50-day moving average price is $0.75 and its 200 day moving average price is $0.84.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The firm had revenue of $11.79 million during the quarter, compared to analyst estimates of $23.16 million. Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. Analysts anticipate that Invivyd, Inc. will post -1.64 EPS for the current fiscal year.

Institutional Trading of Invivyd

A number of hedge funds and other institutional investors have recently made changes to their positions in IVVD. 683 Capital Management LLC boosted its holdings in Invivyd by 2.3% during the second quarter. 683 Capital Management LLC now owns 3,070,000 shares of the company's stock worth $2,195,000 after purchasing an additional 70,000 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Invivyd during the 2nd quarter worth about $147,000. Marshall Wace LLP bought a new position in shares of Invivyd in the 2nd quarter valued at about $158,000. Invesco Ltd. increased its position in shares of Invivyd by 25.5% in the second quarter. Invesco Ltd. now owns 136,755 shares of the company's stock valued at $98,000 after acquiring an additional 27,756 shares during the last quarter. Finally, Catalyst Funds Management Pty Ltd bought a new stake in Invivyd during the second quarter worth about $27,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $5.00 price objective on shares of Invivyd in a report on Thursday, June 26th. D. Boral Capital cut their price target on shares of Invivyd from $9.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $3.85.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.